D-二聚体在肝硬化和肝细胞癌患者血浆中的含量分析

Analysis of plasma D-dimer content in patients with liver cirrhosis and hepatocellular carcinoma

目的探讨肝硬化(LC)和肝细胞癌(HCC)患者血浆D-二聚体(D-dimer)含量与临床分期的关系。方法采用酶联免疫吸附法(ELISA)检测40例LC和57例HCC的血浆D-dimer。结果与正常对照组相比,LC组和HCC组的血浆D-dimer含量均显著升高(P<0.05,P<0.01),特别是HCC组中同时伴有LC的患者。在LC组中,代偿期患者的D-dimer血浆含量明显低于失代偿期(P<0.01);在HCC组中,血浆D-dimer含量随肿瘤分期(Ⅰ、Ⅱ、Ⅲ)的逐步进展而升高(P<0.05,P<0.01)。结论LC和HCC患者血浆D-dimer含量的异常与临床分期密切相关,提示其可作为评价患者病情和鉴别诊断的参考指标。

Objective To investigate the relationship between plasma D-dimer content and clinical stage of liver cirrhosis （LC） and hepatocellular carcinoma （HCC）. Methods The plasma D-dimer content of 40 patients with LC and 57 patients with HOC was detected by using of enzyme linked imrnunosorbent assay（ELISA）. Results The plasma D-dimer conteni was significantly higher in two groups（0.52± 0.16mg·L^-1, 0.81±0.21 mg·L^-1 ） than that in normal control group （0.15 ± 0.07mg·L^-1） （P〈0.05 ,P〈0.01 respectively）, and especially, D-dimer content in HOC patients combined with LC was the highest. In LC group, D-dimer content of compensatory stage patients was significantly lower than that of decompensatory stage（ P〈0.01 ）. In HCC group, D-dimer content increased progressively accompanying with tumor＇s different stages （ Ⅰ , Ⅱ , Ⅲ） （P〈0.05,P〈0.01）. Conclusion The abnormality of plasma D-dimer content is ckxsely correlated to clinical stage of LC and HOC, which indicates that plasma D-dimer may serve as an important parameter for differentiation and evaluating patient＇ s condition.